title: Does treatment of the laryngeal mucosa reduce dystonic symptoms? A prospective clinical cohort study of mannose binding lectin and other immunological parameters with diagnostic use of phonatory function studies.
abstract: This study examined efficacy of the innate immune defence via the mannose binding lectin (MBL) in a cohort of 55 dystonic patients prospectively referred to the clinic with laryngeal mucosal complaints, who were placed on local steroids (budesonid inhaler, 400 μg 2 times daily) and antihistamines (fexofenadin 180 mg mostly 3 times daily) with adjuvant lifestyle corrections. Treatment efficacy of the larynx was assessed based on mucosal findings of the vocal folds examined with phonatory function studies (PhFS) comprising simultaneous high-speed digital images, kymography, electroglottography and voice acoustics combined with a visual score of arytenoids oedema, as these measures are indicative of the magnitude of laryngitis. Lactose and gluten intolerance and immunological analyses of the innate system were made systematically. Results showed that the genetic aspects of immunology did not reveal a role for the innate immune system, represented by the MBL. But an unexpected positive effect of the larynx treatment on dystonia symptoms was found evidenced by reduction of dystonic complaints and more normative results of PhFS, and a reduction of oedema of the inter arytenoids region. Symptoms relieve and better quality of life was observed on follow-up for the dystonia complaints.
authors.affiliation: Ear, Nose, Throat Clinic, The Medical Centre, Østergade 18, 3., 1100 Copenhagen, Denmark. m.f.pedersen@dadlnet.dk
authors.forename: Mette
authors.initials: M
authors.lastname: Pedersen
authors.forename: Martin
authors.initials: M
authors.lastname: Eeg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004421:Dystonia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D007734:Kymography; D007820:Laryngeal Mucosa / Q000187:drug effects / Q000276:immunology*; D007830:Larynx / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D037601:Mannose-Binding Lectin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010699:Phonation / Q000502:physiology*; D011446:Prospective Studies; D016896:Treatment Outcome; D014827:Vocal Cords; D014832:Voice Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D055815:Young Adult
chemical_list: D037601:Mannose-Binding Lectin